Pharma feed

N
Dragonfly Therapeutics, Inc.
MarketScreener· 07 Jul 2020

Bristol Myers Squibb : Dragonfly Therapeutics Expands Collaboration With Bristol-Myers Squibb

By Colin Kellaher Dragonfly Therapeutics Inc. on Monday said it has expanded its research collaboration with Bristol-Myers Squibb Co. to include immunotherapies for multiple sclerosis and neuro-inflammation targets. The privately held company said it will grant Bristol-Myers the option to license exclusive worldwide intellectual-property rights to multiple candidates developed using its proprietary platform for multiple new targets.

  • Dragonfly Therapeutics, Inc.
  • Bristol-Myers Squibb Co
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Amgen, Inc.
Bloomberg Law· 07 Jul 2020

Amgen Ruling Could Prevent Slowdowns in Biosimilar Market Entry

Changes to a biosimilar’s manufacturing locations or labels won’t be enough for innovator biotech companies to block a competitor from bringing their drug to market following a Federal Circuit ruling in a case over an Amgen Inc. cancer drug.

  • Amgen, Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
Takeda Pharmaceutical Co Ltd
Marketresearch· 07 Jul 2020

Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review

Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats.

  • Takeda Pharmaceutical Co Ltd
  • MarketResearch.com
  • Financial and Business Performance
  • News Articles
  • Company Websites
N
Cisco Systems, Inc.
GuruFocus· 07 Jul 2020

Groesbeck Investment Management Corp Buys Sherwin-Williams Co, Merck Inc, Adobe Inc, Sells Booking Holdings Inc, Snap-on Inc, Cisco Systems Inc

Investment company ( ) buys Sherwin-Williams Co, Merck Inc, Adobe Inc, Global Payments Inc, Vertex Pharmaceuticals Inc, sells Booking Holdings Inc, Snap-on Inc, Cisco Systems Inc, Lazard, EQM Midstream Partners LP during the 3-months ended 2020Q2, according to the most recent filings of the investment company, Groesbeck Investment Management Corp .

  • Cisco Systems, Inc.
  • Merck & Co., Inc.
  • Booking Holdings
  • Groesbeck Investment Management Corp
  • Adobe Systems Incorporated
  • Sherwin-Williams Co
  • Snap-On Inc
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Pfizer Inc.
Biospectrum Asia· 07 Jul 2020

Alibaba Cloud, Fintech Academy, Pfizer to accelerate APAC Healthcare Innovations

Alibaba Cloud, Fintech Academy and Pfizer announced today the signing of a Memorandum of Understanding (MoU) leading to the formation of a Healthcare Fintech Alliance (HFA) to catalyze transformation across Asia Pacific’s health tech and fintech sectors.

  • Pfizer Inc.
  • Alibaba Cloud
  • Partnerships and Alliances
  • News Articles
  • Licensed Content
N
Amgen, Inc.
The Center for Biosimilars· 07 Jul 2020

Higher Court Sides With Amgen in Mvasi Case

A federal circuit court has overruled an attempt by Genentech to stop Amgen from selling a bevacizumab biosimilar (Mvasi) in the United States. The ruling was an affirmation of a district court’s earlier opinion affirming Amgen’s right to market the drug.Genentech, which markets the reference drug Avastin, sought an injunction contending that Amgen had failed to provide adequate notice in advance of commercialization.

  • Amgen, Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
BioPharma International· 07 Jul 2020

Emergent and Johnson & Johnson Enter into $480 Million Manufacturing Agreement for COVID-19 Vaccine

Emergent BioSolutions announced on July 6, 2020 that it is entering into a five-year, $480 million manufacturing services agreement with Janssen Pharmaceuticals, a Johnson & Johnson company, for the large-scale drug substance manufacturing of Johnson & Johnson’s investigational COVID-19 vaccine, Ad26.COV2-S.

  • Johnson & Johnson
  • Emergent Biosolutions Inc
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Alexion Pharmaceuticals Inc
Jd Supra· 07 Jul 2020

Episode 149 -- A Deep Dive into Alexion's SEC Settlement for FCPA Violations

+ Follow x Following x Following - Unfollow + Follow x Following x Following - Unfollow + Follow x Following x Following - Unfollow + Follow x Following x Following - Unfollow + Follow x

  • Alexion Pharmaceuticals Inc
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
University of Chicago
Chron· 07 Jul 2020

Bio-IT World Announces 2020 Innovative Practices Award Winners

Bio-IT World has announced the winners of the 2020 Innovative Practices Awards. Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia Alliance were honored. Since 2003, Bio-IT World has hosted an elite awards program, highlighting outstanding examples of how technology innovations and strategic initiatives can be powerful forces for change in the life sciences, from basic biomedical research to drug development and beyond.

  • University of Chicago
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • Massachusetts General Hospital
  • Awards and Recognitions
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
The Guardian (ng)· 06 Jul 2020

Merck Foundation joins hands with African First Ladies to improve cancer care in Africa through providing one, two- and three-year Oncology fellowship and master degree for more than 80 doctors from 2

Merck Foundation (https://www.Merck-Foundation.com/), the philanthropic arm of Merck KGaA Germany in partnership with African First Ladies and Ministries of Health, continue to provide one, two- and three-year Oncology Fellowship and Master degree for African doctors through their Cancer Access Program with the aim to increase the limited number of Oncologists across the continent.

  • Merck & Co., Inc.
  • Partnerships and Alliances
  • News Articles
  • News and Other Websites
Regeneron Pharmaceuticals Inc
Regeneron· 06 Jul 2020

Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)

TARRYTOWN, N.Y. , July 6, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19.

  • Regeneron Pharmaceuticals Inc
  • National Institute of Allergy
  • Clinical Trials
  • Infographics
  • Company Websites
N
Regeneron Pharmaceuticals Inc
News18· 06 Jul 2020

Regeneron Covid-19 Treatment Enters Final Stage of Human Clinical Trials

The pharmaceutical firm Regeneron on Monday announced it was entering the late stages of its human clinical trials investigating a drug to both treat and prevent COVID-19. The drug, called REGN-COV2, is a combination of two antibodies that block the coronavirus' "spike protein" which it uses to invade human cells.

  • Regeneron Pharmaceuticals Inc
  • Clinical Trials
  • News Articles
  • News and Other Websites
Regeneron Pharmaceuticals Inc
Regeneron· 06 Jul 2020

Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)

TARRYTOWN, N.Y. , July 6, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19.

  • Regeneron Pharmaceuticals Inc
  • National Institute of Allergy
  • Clinical Trials
  • Infographics
  • Company Websites
N
AstraZeneca PLC
The Voice of Russia· 06 Jul 2020

UK Pharma Giant AstraZeneca Seeking Biggest Merger in Industry History With US Rival Gilead

Drug companies across the world are racing to develop a vaccine for the coronavirus COVID-19 pandemic. Many have entered into profitably appealing corporate mergers to collaborate to meet the urgent global demand for an inoculation against the virus.

  • AstraZeneca PLC
  • M&A Activities
  • Partnerships and Alliances
  • Competitive Landscape
  • News Articles
  • News and Other Websites
N
Genentech, Inc.
Patentlyo· 06 Jul 2020

Biosimilars and Temporary Restraining Orders

by Dennis Crouch Genentech and City of Hope v. Immunex and Amgen (Fed. Cir. 2020) Genentech’s bevacizumab (Avastin) is a large-molecule biologic cancer chemotherapy. The FDA approved (licensed) Amgen’s biosimilar (aka generic) version – that is sold as Mvasi.

  • Genentech, Inc.
  • Amgen, Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Hoffmann-La Roche Ltd
Bloomberg Law· 06 Jul 2020

Roche’s Genentech Loses Appeal Ruling Over Amgen’s Mvasi (2)

Roche Holding AG ’s Genentech unit lost its appeals court bid to halt Amgen’s Inc.’s biosimilar of the cancer drug Avastin. Genentech had argued that Amgen didn’t provide adequate notice, as required by law, before it began selling the biosimilar Mvasi.

  • Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Roche Products Ltd
  • Amgen, Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Regeneron Pharmaceuticals Inc
Gmpnews· 06 Jul 2020

REGN-COV2 Antiviral Antibody Cocktail Enters Phase 3 Human Trials

Regeneron Pharmaceuticals, Inc. announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron’s investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2’s ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient’s housemate), and is being run jointly with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

  • Regeneron Pharmaceuticals Inc
  • National Institute of Allergy
  • Clinical Trials
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
Arabfinance· 06 Jul 2020

GSK Egypt turns to profit

ArabFinance: GlaxoSmithKline Egypt (GSK Egypt) (BIOC) posted a consolidated net profit of EGP 23,142,498 for Quarter one (Q1) of 2020, versusa net loss of EGP 7,553,338, according to the company’s financial results on July 6th. Standalone net profit reached EGP 31,911,062 in Q1 2020, against net loss of EGP 15,418,002 incurred in Q1 2019.

  • GlaxoSmithKline PLC
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
  • Hoffmann-La Roche Ltd
  • Roche Products Ltd
  • Hiring
  • Infographics
  • Youtube
N
Hoffmann-La Roche Ltd
Bloomberg Law· 06 Jul 2020

Roche’s Genentech Loses Appeals Court Ruling Over Amgen’s Mvasi

Roche Holding AG ’s Genentech unit lost its appeals court bid to halt Amgen’s Inc.’s biosimilar of the cancer drug Avastin. Genentech had argued that Amgen didn’t provide adequate notice, as required by law, before it began selling the biosimilar Mvasi.

  • Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Roche Products Ltd
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
Johnson & Johnson
Johnson & Johnson· 06 Jul 2020

Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Mid

This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.

  • Johnson & Johnson
  • Global Fund
  • Partnerships and Alliances
  • Press Releases
  • Company Websites
N
Regeneron Pharmaceuticals Inc
Endpoints News· 06 Jul 2020

Covid-19 roundup: Teamed up with NIH, Regeneron launches PhIII prevention trial for antibody cocktail

We are unleashing our nation’s scientific brilliance and will likely have a therapeutic and/or vaccine solution long before the end of the year. — Donald Trump, July 4 Next week administration officials plan to promote a new study they say shows promising results on therapeutics, the officials said.

  • Regeneron Pharmaceuticals Inc
  • Partnerships and Alliances
  • New Offerings
  • News Articles
  • News and Other Websites
N
Bayer AG
Bnnbloomberg· 06 Jul 2020

It Took a Pandemic to Settle Bayer’s Roundup Suits

(Bloomberg Opinion) -- In late June, Bayer AG agreed to pay $9.5 billion to settle about 100,000 lawsuits that accused Roundup, the popular herbicide it acquired when it bought Monsanto in 2018, of causing non-Hodgkin lymphoma.

  • Bayer AG
  • Regulatory and Legal
  • Negative News
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Biospectrum Asia· 06 Jul 2020

Proteona positions among top 44 science-based global spinoff companies by Spinoff Prize

Proteona has been selected by the Spinoff Prize as one of the top 44 science-based spinoff companies from around the world. The Spinoff Prize is established by Nature Research in partnership with the Merck Group. The award highlights spinoffs who take top-quality scientific research to the market and make a positive impact.

  • Merck & Co., Inc.
  • Nature Research
  • Awards and Recognitions
  • News Articles
  • Licensed Content
N
Mylan Specialty LP
Reuters· 06 Jul 2020

Mylan prices its generic remdesivir in India at $64 per 100 mg vial

BENGALURU (Reuters) - Mylan NV (MYL.O) said on Monday it would launch a generic version of Gilead Sciences Inc’s (GILD.O) COVID-19 antiviral remdesivir in India at 4,800 rupees ($64.31), about 80% below the price tag on the drug for wealthy nations.

  • Mylan Specialty LP
  • Mylo
  • Gilead Sciences, Inc.
  • New Offerings
  • News Articles
  • News and Other Websites
1 2 3 4 5